In the management of HPV-driven OPSCC surveillance
Let Their Blood TTMV® Score Help Achieve a New Standard of Care
Monitoring TTMV-HPV DNA Scores with the NavDx test at routine surveillance visits
has demonstrated unrivaled test performance metrics1-3
- ≥97% Specificity and ≥89% Sensitivity to more accurately detect true disease status1,2
- ≥98% NPV with no recurrence when TTMV-HPV DNA Scores remained undetectable1,2
- ≥95% PPV for cancer recurrence, when patients had 1 positive test result1,2
- With unrivaled NPV and PPV, serial NavDx testing during surveillance could help optimize the use of imaging, by mitigating the need for unnecessary imaging exams1-3
NavDx surveillance testing, with its high PPV, can reduce the risk of unnecessary invasive procedures, whereas its high NPV can offer patients greater confidence in their response to treatment and current disease management.3,5
Serial NavDx testing assists in earlier detection of patients with recurrent disease2,3
Why wait for physical symptoms to appear? A single positive TTMV-HPV DNA Score was the first indication of recurrence in 97% (57/59) of asymptomatic patients3 *†
*Of 1,076 patients tested during surveillance, 80 (7.4%) had at least one positive TTMV-HPV DNA Score. Of these, 59 (74%) had either indeterminant (IND) disease status or no evidence of disease (NED) at time of their positive test Score, while 21 (26%) were noted as having clinically active disease at time of their first positive Score. Nearly half, 38 (48%) were tested >12 months after completion of definitive therapy, while 27 (34%) and 15 (19%) were tested at 6-12 months, and 3-6 months, respectively.
†57 of the 59 (96.66%) patients with IND or NED status, who tested positive for TTMV-HPV DNA, were later proven to have recurrent disease (on imaging and/or biopsy), suggesting the presence of clinically occult recurrence at time of their positive test result. Longer follow-up was needed to identify recurrent cancer in 2 of the remaining 4 IND and NED patients under surveillance. All 21 patients with active disease reported at the time of TTMV-HPV DNA testing were confirmed to have recurrent disease.
NavDx testing reliably informs disease status enabling you to intervene earlier with imaging, physical exams, and salvage therapy; and reassure patients their disease is being effectively managed2,3
Use NavDx testing to optimize the clinical management of HPV-driven cancer across the patient care continuum4
Pretreatment
CONFIRM the tumor HPV genotype4 and establish baseline TTMV Score
During Treatment
ASSESS treatment response4
IDENTIFY the presence of molecular residual disease4
Optimize the clinical management of HPV+ oropharyngeal squamous cell carcinoma
(OPSCC) across the patient care continuum4,6,7
NavDx testing reliably informs disease status, enabling you to intervene earlier with imaging, physical exams and salvage therapy, and reassure patients their disease is being effectively managed.2,3
Tumor tissue modified viral (TTMV)-HPV DNA is a unique biomarker of tumors driven by HPV.4
(HPV+) tumor cells die, TTMV-HPV
DNA fragments are shed
into the blood
When tumor cells die, they release fragments of their DNA into the bloodstream. This circulating tumor DNA can be measured in blood samples and used to detect a tumor, guide tumor-specific treatment, and monitor for treatment response and cancer-free survival.4
The TTMV-HPV DNA biomarker is unique to human papillomavirus (HPV)-driven cancers like oropharyngeal squamous cell carcinoma (OPSCC), or anal squamous cell carcinoma (ASCC) and is specific to the HPV-genotype involved in the patients cancer diagnosis. HPV-16 is the most common genotype; however, other high-risk HPV genotypes include, HPV-18, HPV-31, HPV-33, and HPV-35.7
Monitoring changes in your HPV-positive cancer patients circulating TTMV-HPV DNA Scores can indicate molecular residual disease and cancer recurrence, enabling you to intervene earlier, which may result in improved outcomes4
Start Optimizing
HPV+ Cancer Surveillance Today
Testing Schedule
Clinical practice guidelines and CMS coverage policy for recurrence detection include surveillance at specified intervals:
During Surveillance
≤2 years post treatment: every 3 months
3-5 years post treatment: every 6 months
6+ years post treatment: 1 time per year
Naveris Provider Portal
An ordering experience that respects your time
Convenient Test Kit Ordering
Always be prepared - order NavDx Test Kits directly from the portal, for your practice
Streamlined ordering process
Complete, sign and submit test orders from our secure provider portal
Realtime access to order status, test results and patients’ testing histories
Review order status, receive and download test results,
and view testing histories for your patients
Automate serial testing during surveillance
The MRD Surveillance Notification Program enables you
to receive a patient's Test Requisition Forms (TRFs)
during surveillance, based on your specified intervals.
A simple blood draw, performed in-office or through our nationwide mobile phlebotomy services
- Test sample requires one 10-mL tube of whole blood
- For practices WITH blood collection capabilities, order NavDx test kits for delivery to your practice
- For practices WITHOUT blood collection capabilities, patients may use our Mobile Phlebotomy Service for convenient, in-home blood collection
Optimize the clinical management of HPV+ head and neck cancer and reassure patients their disease is being effectively monitored by tracking their TTMV-HPV DNA Score with the NavDx blood test!
Optimize HPV+ Oropharyngeal Cancer Care with the NavDx Test Results Report
Easy-to-interpret, actionable test result helps inform clinical decisions
- Quick summary of test findings
The NavDx Test Result reports the patient's TTMV-HPV DNA status and the TTMV-HPV DNA Score. - The graph
Longitudinal plot of the patient’s TTMV-HPV DNA Score for each NavDx test. - Test results and interpretation
Results include:
- TTMV-HPV DNA Score
- Risk Score interpretation
- Tumor HPV genotype
Naveris also provides a brief qualitative written interpretation of the test result
NavDx testing reliably informs disease status so you can optimize the utility of imaging, physical exams and therapy, reassuring patients their disease is being effectively managed.2,3
Optimize HPV+
cancer care with comprehensive
resources and
support for your
practice
Practice Resources
We’ve developed a range of useful tools to help you incorporate NavDx testing into your practice
NavDx Testing in Clinical Practice
Review real-world cases to see how your peers are utilizing NavDx testing to help optimize HPV-driven oropharyngeal cancer care
Video Library
View our video library to learn more about the benefits of using the NavDx test in your clinical practice
Publications
Review the latest publications to learn how NavDx testing is enabling physicians to optimize HPV+ cancer surveillance